Best Practices in the Treatment and Management of Ovarian Cancer: Expert Managed Care Strategies on the Evolving Role of PARP Inhibitors.
The introduction of PARP inhibitors has significantly changed the management of advanced ovarian cancer. These agents improve progression-free (PFS) survival when used as maintenance therapy after first-line platinum-based chemotherapy. The most benefit is for those who have genetic mutations that m...
| Publicado en: | Journal of Managed Care Medicine Vol. 28; no. 4; pp. 4 - 10 |
|---|---|
| Autor principal: | |
| Formato: | CEU pictorial tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | The introduction of PARP inhibitors has significantly changed the management of advanced ovarian cancer. These agents improve progression-free (PFS) survival when used as maintenance therapy after first-line platinum-based chemotherapy. The most benefit is for those who have genetic mutations that make the tumor more susceptible to PARP inhibition. |
|---|